Abstract accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain.

"We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR Symposium and sharing these data with the international oncology community," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "This meeting brings together leading investigators, clinicians and researchers focused on advancing new approaches in cancer treatment, and we welcome the opportunity to discuss our program with the broader oncology community in Barcelona."

Presentation Details:

Title:Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)
Presenting Author:Timothy A. Yap, MBBS, PhD, FRCP

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and Investigator in the ACESOT-1051 study
Session:Plenary Session (Oral Presentation)
Date and Time:Friday, November 20, 2026, 3:00 PM - 3:10 PM CET
Location:Room 111 + 112, CCIB, Barcelona.